Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P110005/S015

Gelsyn-3

Ibsa Institut Biochimique SA · Decision date Jul 24, 2026

FDA DECISIONP110005/S015

What did the FDA decide?

FDA records P110005/S015 as a supplement to PMA P110005, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 24, 2026.

FDA approval order statement

Approved for the addition of a new dispensing area, Room A107, for the sampling and weighing of raw materials used in the manufacture of GELSYN-3 (sodium hyaluronate 0.84%) at the IBSA Farmaceutici Italia Srl facility in San Grato-Lodi, Italy, under the same FEI as the currently approved dispensing area
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Jul 24, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P110005/S015
Regulatory pathway
PMA supplement
Product code
MOZ
Decision code
OK30
Decision date
Jul 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Acid, hyaluronic, intraarticular.

Product code
MOZ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P110005/S015 received

    Application receipt date recorded by FDA.

  2. P110005/S015 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P110005. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code MOZ

Product / regulatory recordCompanyPathwayDecision dateSource
Gel-OneP080020/S056
Seikagaku Corp.PMA supplementSep 4, 2026FDA
SUPARTZ FXP980044/S067
Seikagaku Corp.PMA supplementSep 4, 2026FDA
Ferring Pharmaceuticals, Inc.PMA supplementSep 2, 2026FDA
Anika Therapeutics, Inc.PMA supplementAug 28, 2026FDA
GEL-ONEP080020/S057
Seikagaku Corp.PMA supplementAug 26, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ibsa Institut Biochimique SA

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Via Al Ponte 13, Ch-6903, Lugano Ticino, 6903

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records